CordLife, Asia Pacific’s largest network of stem cell banks, on Wednesday launched the most advanced umbilical cord banking technology in the country. The technology has the ability to isolate two cell types that help in hastening the healing process of diabetic foot ulcers.
The patented technology allows access epithelial stem cells that can rejuvenate skin and mucus membranes for treating non-healing wounds as is seen in diabetic ulcer patients, said Steven Fang, group CEO, CordLife. With over 4 crore people in the country diagnosed with diabetes and 1 in every 6 estimated to have an ulcer during the lifetime, CordLife
CRYO-SAVE Group, the Netherlands-based stem cell company with a large Indian presence, plans to increase the number of stem cell donors
in the country by opening more representative offices. The company expects this would increase the number of clients and also extend its reach beyond the current five cities, group CEO Rob Koremans told ET.
Cryo-Save Group plans to invest e 2 million (about Rs 13 crore) in its Bangalore-based subsidiary for over three years.
Chennai-based LifeCell International, India’s largest umbilical cord stem cell bank is looking at raising funds for its new venture public stem cell banking. The company said the funds will be used for infrastructure, expansion and marketing.
The public stem cell banking—which will allow anyone to receive stem cells that match their requirements from a storage facility—is being implemented through LifeCell Foundation, a non-profit venture.
LifeCell has already raised Rs 18 crore. Of this, Shriram group chairman R Thiagarajan, one of the promoters of LifeCell, has contributed Rs 2.5 crore and Mayur Abhaya, MD & CEO of LifeCell, has given 2.5 crore
International Stem Cell Corporation, announced today its wholly-owned subsidiary, Lifeline Cell Technology (Lifeline), has signed a distribution agreement with Tokyo-based Veritas Corporation to distribute its human cell culture products throughout Japan.
Lifeline, located in Maryland and California, specializes in the development, manufacture, and distribution of products to culture human cells for the study of human disease, including products to culture primary human cells and human stem cells. These products are being requested by customers overseas, including customers in Japan, Korea and India and this agreement is the first step in Lifeline’s plan to meet these requests.
The extensive research on stem cells has revolutionised the way life-threatening diseases like leukaemia and aplastic anaemia can be treated.
But there are several steps before these diseases can be treated using stem cells.
To begin with, the Human Leukocyte Antigen (HLA)-typing of the patient is done. Doctors then get into the process of finding a matched donor from the computerised list made available to them by National Marrow Donor Programme (NMDP), U.S., and New York Cord Blood Bank.
If registration of potential bone marrow donors has been in place for a long time, the emergence of a number of cord blood